Core Center

以患者为导向的生物医学研究与诊断，疾病机制，监测疾病活动和新的治疗方法在风湿性疾病是约翰霍普金斯风湿病学分部的标志。这项研究是围绕着硬皮病（Fred Wigley博士），狼疮（Michelle Petri博士），关节炎（Joan Bathon博士）和血管炎（John Stone博士）的完善的疾病特异性卓越中心进行的。这些临床队列与安东尼罗森和利维亚·卡肖拉-罗森博士指导的强大的基础科学项目密切相关。近年来，该计划得到了出色的机构支持，实现了显着增长，对共享设备和基础设施的投资，以及在部门内外启动了多个协同项目。我们的风湿病研究核心中心（RDRCC）提案利用了风湿病科强大的生物医学研究基础，以及约翰霍普金斯更广泛的科学界的其他杰出人才。 霍普金斯RDRCC提案包括由安东尼罗森和约翰斯通博士领导的管理核心（核心A），并包括2个科学核心：1）由詹姆斯·马奥尼、马克·索洛斯基和利维亚·卡肖拉-罗森博士领导的生物测定核心（核心B）;和2）由凯瑟琳·巴恩斯博士领导的基因分型/基因组学核心（核心C），旨在促进该部门疾病中心内外的新研究。核心A将通过核心促进跨学科研究，提供财务管理援助，提供信息技术解决方案，以最大限度地提高转化研究的效率，并协调项目丰富活动。行政核心还将管理试点和可行性计划。第一年选择的试点研究与疾病中心和核心密切相关。试验1将优化测定，以直接离体定量儿科SLE患者中凋亡细胞的清除。试验#2将探索粒酶B的遗传多态性与硬皮病中特定表型的关联。核心B将协助患者样本采集、处理、储存和分发，并提供多种免疫学检测，包括FACS、ELISA、免疫组织学和多重细胞因子检测。核心C将在各种人类疾病和对照组织以及一些小鼠模型中进行，分析和解释基因表达研究。核心C还将监督在明确的人类风湿性表型中的遗传关联研究的设计、执行和分析。

Patient-oriented biomedical investigation related to diagnosis, disease mechanisms, monitoring disease activity and new therapeutic approaches in rheumatic disease is the hallmark of the Johns Hopkins Division of Rheumatology. This research is structured around well-established disease-specific Centers of Excellence in scleroderma (Dr. Fred Wigley), lupus (Dr. Michelle Petri), arthritis (Dr. Joan Bathon), and vasculitis (Dr. John Stone). These clinical cohorts are coupled closely with a robust basic science program directed by Drs. Antony Rosen and Livia Casciola-Rosen. In recent years, this program has received outstanding institutional support, enabling significant growth, investment in shared equipment and infrastructure, and the initiation of multiple synergistic projects both within and outside the Division. Our Rheumatic Disease Research Core Center (RDRCC) proposal capitalizes upon the strong biomedical research base within the Division of Rheumatology, as well as additional outstanding talent from the broader scientific community at Johns Hopkins. The Hopkins RDRCC proposal comprises an Administrative Core (Core A) led by Drs. Antony Rosen and John Stone, and includes 2 Scientific Cores: 1) a Bioassay Core (Core B), led by Drs. James Mahoney, Mark Soloski, and Livia Casciola-Rosen; and 2) a Genotyping/Genomics Core (Core C), led by Dr. Kathleen Barnes, designed to foster new research within and beyond the Division's Disease Centers. Core A will promote interdisciplinary research through the cores, provide assistance with financial management, provide information technology solutions to maximize efficiency of translational research, and coordinate program enrichment activities. The Administrative core will also manage the Pilot and Feasibility program. Pilot studies chosen for the first year are tightly linked to the disease Centers and Cores. Pilot #1 will optimize assays to quantify clearance of apoptotic cells directly ex vivo in pediatric SLE patients. Pilot #2 will explore the association of genetic polymorphisms in granzyme B with specific phenotypes in scleroderma. Core B will provide assistance with patient sample acquisition, processing, storage, and distribution, as well as the provision of multiple immunological assays, including FACS, ELISA, immunohistology, and multiplex cytokine assays. Core C will perform, analyze, and interpret gene expression studies in a variety of human disease and control tissues and some mouse models. Core C will also oversee the design, performance and analysis of genetic association studies in well-defined human rheumatic phenotypes.